Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
US-Listed Public Company Profile built from SEC and market records · June 2026

Royalty Pharma plc (RPRX)

$64.76 +1.41% NASDAQ: RPRX · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: RPRX
  • 100 employees
$26.1BMarket cap
$2.4BRevenue · FY2025
$770.9MNet income
100Employees
RPRXNASDAQ
2020IPO

About Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2025
$2.4B
Net income
$770.9M
Total assets
$19.6B
Market cap
$26.1B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: RPRX
$64.76 +1.41%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$34.90 $64.76

52-week range

Market cap
$26.1B
Dividend yield
1.45%
Shares outstanding
402.7M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Jun 16, 2020

Royalty Pharma plc (RPRX) Stock Price

  • Profitable — net income of $770.9M in FY2025.
  • Trading near its 52-week high.
  • Pays a dividend yielding about 1.45% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Royalty Pharma plc.

Write a review
Newsroom

News about Royalty Pharma plc

News & sentiment via Polygon.io

FAQ

Royalty Pharma plc: frequently asked questions

Is Royalty Pharma plc an American company?

Yes — Royalty Pharma plc is an American company headquartered in New York, New York. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.

Where is Royalty Pharma plc headquartered?

Royalty Pharma plc is headquartered in New York, New York, United States.

Is Royalty Pharma plc publicly traded?

Yes — Royalty Pharma plc is a publicly traded company. Its stock trades under the ticker symbol RPRX on the NASDAQ.

What does Royalty Pharma plc do?

Royalty Pharma plc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →